Award Number: DAMD17-89-C-9050

TITLE: A Medical Research and Evaluation Facility and Studies Supporting the Medical Chemical Defense Program

PRINCIPAL INVESTIGATOR: Carl T. Olson, DVM, Ph.D.

CONTRACTING ORGANIZATION: Battelle Memorial Institute
Columbus, Ohio 43201-2693

REPORT DATE: November 1998

TYPE OF REPORT: Final, Task 97-56

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**Title and Subtitle**
A Medical Research and Evaluation Facility and Studies Supporting the Medical Chemical Defense Program

**Author(s)**
Carl T. Olson, DVM, Ph.D.

**Performing Organization Name(s) and Address(es)**
Battelle Memorial Institute
Columbus, Ohio 43201-2693

**Sponsoring / Monitoring Agency Name(s) and Address(es)**
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

**Supplementary Notes**

**DISTRIBUTION / AVAILABILITY STATEMENT**
Approved for public release; distribution unlimited

**Subject Terms**
Nerve Agents, Antidotes, CD Agents, CSM Sheep, Vesicants, Decontamination, Skin Protection, Desert Shield, BL3, BD, Advanced Development, RADV, CD, RADIV

**Security Classification of Report**
Unclassified

**Security Classification of This Page**
Unclassified

**Security Classification of Abstract**
Unclassified

**Number of Pages**
4

**Price Code**
Unlimited
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Carl T. Olson, DVM, Ph.D.

PI - Signature Date
Date       November 4, 1998
To         Col. Richard Stotts
           Army Medical Research and Materiel
           Command
From       Michael Crenshaw /DC /
Subject    Contract DAMD17-89-C-9050, Task 97-56

This memo serves as an unclassified summary report for Task 97-56 under Contract DAMD17-89-C-9050. A classified final report has been prepared and awaits delivery instructions. The final report contains data and detailed discussions to demonstrate that the goals of this program have been met.

The goals of this program were to deliver 5-10 grams each of Compound II and Compound IV. Each compound was to have a purity of 95% or greater as determined by gas chromatography-mass spectrometry (GC/MS) and nuclear magnetic resonance spectroscopy (NMR).

On 11 February 1998, 7.88 grams of Compound II with a purity of 99.3% (lot no. 47775-64-06) and 7.37 grams of Compound IV with a purity of 96.5% (lot no. 47775-76-25) were delivered to Battelle’s Medical Research and Evaluation Facility, West Jefferson, Ohio. Supporting spectroscopic data was also sent on the same day.